Fluoromedroxyprogesterone acetate

Fluoromedroxyprogesterone acetate

Clinical data
Other names	FMPA; 9α-Fluoromedroxyprogesterone acetate; 9α-FMPA; 9α-Fluoro-6α-methyl-17α-hydroxyprogesterone acetate; 17α-Acetoxy-9α-fluoro-6α-methylpregn-4-ene-3,20-dione; 9α-Fluoro-6α-methyl-3,20-dioxopregn-4-en-17-yl acetate
Routes of administration	By mouth
Drug class	Angiogenesis inhibitor; Progestogen; Progestogen ester; Progestin; Glucocorticoid
Identifiers
IUPAC name [(6S,8S,9R,10S,13S,14S,17R)-17-Acetyl-9-fluoro-6,10,13-trimethyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate
CAS Number	171611-77-1 Y
PubChem CID	9865941
ChemSpider	8041632
UNII	8Q7RBX3VSU
Chemical and physical data
Formula	C24H33FO4
Molar mass	404.522 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@]2([C@@]4(C1=CC(=O)CC4)C)F)C)(C(=O)C)OC(=O)C
InChI InChI=1S/C24H33FO4/c1-14-12-20-18-7-9-24(15(2)26,29-16(3)27)22(18,5)10-11-23(20,25)21(4)8-6-17(28)13-19(14)21/h13-14,18,20H,6-12H2,1-5H3/t14-,18-,20-,21-,22-,23+,24-/m0/s1 Key:OITYTGLRWMEVSQ-XDBMOVBSSA-N

Fluoromedroxyprogesterone acetate (FMPA, 9α-fluoromedroxyprogesterone acetate, or 9α-FMPA) is a synthetic steroid medication which was under development by Meiji Dairies Corporation in the 1990s and 2000s for the potential treatment of cancers but was never marketed. It is described as an antiangiogenic agent, with about two orders of magnitude greater potency for inhibition of angiogenesis than its parent compound medroxyprogesterone acetate. FMPA showed about the same affinities for the progesterone and glucocorticoid receptors as MPA. It reached the preclinical phase of research prior to the discontinuation of its development.

See also

• Anecortave acetate

External links

• Fluoromedroxyprogesterone acetate (FMPA) - AdisInsight